Jon Vincelette

Jon Vincelette has extensive experience in the field of in-vivo pharmacology and lab operations. Jon is currently working as the Director of In Vivo Pharmacology and Lab Operations at Alector. Prior to this, Jon Vincelette held the position of Director of In-Vivo Translational Sciences at Graphite Bio, where they established and led a new In Vivo research group focused on driving non-clinical drug development initiatives for CRISPR-based cellular therapies in oncology and rare hematologic disorders. Jon also designed and executed studies investigating the efficacy, safety, pharmacokinetics, and pharmacodynamics of cellular therapies.

Before their role at Graphite Bio, Jon Vincelette was the Founder and owner of PacificInsects.com, a private company that focused on researching and developing improved insect culture systems to meet the global demand for alternative protein sources.

Prior to founding PacificInsects.com, Jon Vincelette worked at BioMarin Pharmaceutical Inc. for over a decade. Jon held several positions within the company, including Associate Director, Head of Vivarium, Senior Scientist I, Scientist II, and Scientist I. In these roles, they designed, conducted, and interpreted pharmacology research for multiple therapeutic projects utilizing various modalities. Their research focused on ERT for MPS IIIA, Citrulinemia therapies, and gene therapies for Hemophilia A.

Before joining BioMarin Pharmaceutical Inc., Jon Vincelette worked at Arete Therapeutics as a Scientist, where they investigated the in-vivo efficacy and mechanism of action of novel SEH inhibitors for the treatment of cardiovascular and metabolic diseases. Jon also managed the group conduct and facility needs within a leased vivarium space.

Jon Vincelette began their career at Bayer Healthcare as a Sr. Associate Research Scientist, where they evaluated the efficacy and safety of novel therapeutics in the treatment of cardiovascular and oncology disease indications. Jon also participated in the design and development of an expanded vivarium.

Prior to their role at Bayer Healthcare, Jon Vincelette worked at Berlex Biosciences/Schering Ag as a Senior Associate Scientist, where they evaluated the efficacy and safety of novel therapeutics in the treatment of cardiovascular and oncology disease indications. Jon also investigated the efficacy of second-generation recombinant Factor VIII in hemophilia-A mice and demonstrated the efficacy and safety of anti-thrombotics and thrombolytics.

Jon Vincelette started their career as an Associate Scientist at Berlex Biosciences and later worked at Baxter Inc. as a Research Associate III, where they characterized the in-vivo efficacy of oxygen delivery by recombinant human hemoglobin in rodent models of hemorrhagic trauma and investigated ischemia-reperfusion injury protection.

Before entering the pharmaceutical industry, Jon Vincelette worked at Merck as a Quality Assurance Auditor, where they audited non-clinical in-vivo research data packages for compliance with GLP regulations. Jon also prepared relevant FDA clinical study reports for canine anthelmintics in the Animal Health Products division.

Jon Vincelette holds a Bachelor's of Science degree in Biology/Animal Science from the University of Delaware, which they obtained between 1988 and 1993. In 2022, they pursued further education and completed a Certificate program in Genetics and Genomics from Stanford University, where they studied until 2033. In the same year, Jon also obtained a Certificate in Professional Management from James Madison University. Additionally, in July 2023, Jon Vincelette obtained the certification "XGEN101 - Fundamentals of Genetics: The Genetics You Need To Know" from Stanford Online.